Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pasithea Therapeutics (KTTA) Change in Accured Expenses (2021 - 2024)

Pasithea Therapeutics (KTTA) has disclosed Change in Accured Expenses for 4 consecutive years, with $483373.0 as the latest value for Q4 2024.

  • Quarterly Change in Accured Expenses fell 29.22% to $483373.0 in Q4 2024 from the year-ago period, while the trailing twelve-month figure was -$1.4 million through Dec 2024, down 233.76% year-over-year, with the annual reading at $11233.0 for FY2025, 100.78% up from the prior year.
  • Change in Accured Expenses hit $483373.0 in Q4 2024 for Pasithea Therapeutics, up from -$758354.0 in the prior quarter.
  • In the past five years, Change in Accured Expenses ranged from a high of $682903.0 in Q4 2023 to a low of -$1.0 million in Q2 2024.
  • Historically, Change in Accured Expenses has averaged $51557.1 across 4 years, with a median of $51899.5 in 2021.
  • Biggest five-year swings in Change in Accured Expenses: surged 1437.84% in 2023 and later plummeted 1572.63% in 2024.
  • Year by year, Change in Accured Expenses stood at -$80816.0 in 2021, then soared by 446.66% to $280153.0 in 2022, then soared by 143.76% to $682903.0 in 2023, then fell by 29.22% to $483373.0 in 2024.
  • Business Quant data shows Change in Accured Expenses for KTTA at $483373.0 in Q4 2024, -$758354.0 in Q3 2024, and -$1.0 million in Q2 2024.